- Home
- UNCY vs ELEV Comparison
UNCY vs ELEV Comparison
Compare UNCY & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- ELEV
- Stock Information
- Founded
- UNCY 2016
- ELEV 2019
- Country
- UNCY United States
- ELEV United States
- Employees
- UNCY N/A
- ELEV N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- ELEV Health Care
- Exchange
- UNCY Nasdaq
- ELEV Nasdaq
- Market Cap
- UNCY 31.9M
- ELEV 37.6M
- IPO Year
- UNCY 2021
- ELEV 2021
- Fundamental
- Price
- UNCY $0.66
- ELEV $0.63
- Analyst Decision
- UNCY Strong Buy
- ELEV Strong Buy
- Analyst Count
- UNCY 4
- ELEV 5
- Target Price
- UNCY $5.50
- ELEV $7.20
- AVG Volume (30 Days)
- UNCY 1.5M
- ELEV 720.2K
- Earning Date
- UNCY 11-13-2024
- ELEV 11-06-2024
- Dividend Yield
- UNCY N/A
- ELEV N/A
- EPS Growth
- UNCY N/A
- ELEV N/A
- EPS
- UNCY N/A
- ELEV N/A
- Revenue
- UNCY N/A
- ELEV N/A
- Revenue This Year
- UNCY N/A
- ELEV N/A
- Revenue Next Year
- UNCY N/A
- ELEV N/A
- P/E Ratio
- UNCY N/A
- ELEV N/A
- Revenue Growth
- UNCY N/A
- ELEV N/A
- 52 Week Low
- UNCY $0.20
- ELEV $0.44
- 52 Week High
- UNCY $1.82
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- UNCY 52.04
- ELEV 49.52
- Support Level
- UNCY $0.62
- ELEV $0.61
- Resistance Level
- UNCY $0.87
- ELEV $0.70
- Average True Range (ATR)
- UNCY 0.08
- ELEV 0.08
- MACD
- UNCY -0.01
- ELEV 0.00
- Stochastic Oscillator
- UNCY 15.45
- ELEV 25.10
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.